TY  - GEN
AU  - Sannino, Giuseppina
AU  - Marchetto, Aruna
AU  - Ranft, Andreas
AU  - Jabar, Susanne
AU  - Zacherl, Constanze
AU  - Alba-Rubio, Rebeca
AU  - Stein, Stefanie
AU  - Wehweck, Fabienne S
AU  - Kiran, Merve M
AU  - Hölting, Tilman L B
AU  - Musa, Julian
AU  - Romero-Pérez, Laura
AU  - Cidre-Aranaz, Florencia
AU  - Knott, Maximilian M L
AU  - Li, Jing
AU  - Jürgens, Heribert
AU  - Sastre, Ana
AU  - Alonso, Javier
AU  - Da Silveira, Willian
AU  - Hardiman, Gary
AU  - Gerke, Julia S
AU  - Orth, Martin F
AU  - Hartmann, Wolfgang
AU  - Kirchner, Thomas
AU  - Ohmura, Shunya
AU  - Dirksen, Uta
AU  - Grünewald, Thomas G P
PY  - 2019
DO  - 10.1016/j.ebiom.2019.08.002
SN  - 2352-3964
UR  - http://hdl.handle.net/20.500.12105/9164
AB  - BACKGROUND: Up to 30-40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time span of 2-10 years. This is in part caused by the absence of prognostic biomarkers that can identify high-risk...
LA  - eng
PB  - Elsevier
KW  - Biomarker
KW  - Ewing sarcoma
KW  - Patient outcome
KW  - Risk-stratification
KW  - SOX2
KW  - Biomarkers
KW  - Biomarkers, Tumor
KW  - Female
KW  - Humans
KW  - Immunohistochemistry
KW  - Male
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Risk Factors
KW  - SOXB1 Transcription Factors
KW  - Sarcoma, Ewing
KW  - Gene Expression
TI  - Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients
TY  - research article
ER  -